Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer-MedSci.cn

Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer

Ahn, DH; Erlander, M; Ridinger, M; Samuelsz, E; Barzi, A; Bekaii-Saab, T; Lenz, HJ

ANNALS OF ONCOLOGY, 2020; 31 (): S427

科室
- - 订阅+
  - 更多科室
工具
服务